Literature DB >> 26688499

Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings.

Samuel R Weber1, Allison M Wehr2, Anne-Marie Duchemin3.   

Abstract

BACKGROUND: An increasing number of prescribers are using antipsychotics for treatment of anxiety disorders, despite lack of FDA-approved indications and mixed efficacy results from clinical trials. The objective of this study was to examine the prevalence of antipsychotics prescription in psychiatric inpatients and outpatients with anxiety disorders.
METHODS: This is a retrospective study of de-identified data from patients with a DSMIV-TR anxiety disorder diagnosis in an academic psychiatric setting in 2013. The final cohort of patients, after exclusion of bipolar/psychotic comorbidity, includes 1699 patients. Logistic regression models were used to explore associations between antipsychotic prescription and patient characteristics.
RESULTS: Among non-psychotic/non-bipolar patients with anxiety disorder, 53.6% of inpatients and 16.6% of outpatients received antipsychotic medication. Rates varied with the disorder. Outpatients with post-traumatic stress disorder (OR: 2.24, 95% CI: 1.66-3.01) and obsessive compulsive disorder (OR: 2.80, 95% CI: 1.86-4.19) received antipsychotic prescriptions more often than those without these diagnoses. Comorbidity with depression was common while comorbidity with borderline personality disorder was rare; both increased odds of receiving prescription of antipsychotics (OR: 1.57, 95% CI: 1.16-2.12 for depression; OR: 2.63, 95% CI 1.42-4.88 for borderline personality disorder, respectively). Additionally, age was significantly associated with increased odds of being on an antipsychotic. Quetiapine and aripripazole were the most prescribed antipsychotics and very few patients received rescue medication for extrapyramidal symptoms. LIMITATIONS: Lack of specific indications for the psychotropic prescriptions.
CONCLUSIONS: A substantial percentage of patients with anxiety disorders are prescribed antipsychotics, especially among inpatients. This practice may reflect the severity of the anxiety disorder or the high prevalence of comorbidity. Based on frequency of rescue medication prescription, treatment seemed well tolerated for extra-pyramidal neurological side-effects.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comorbidity; Extra-pyramidal symptoms; Obsessive compulsive disorder; Post-traumatic stress disorder

Mesh:

Substances:

Year:  2015        PMID: 26688499     DOI: 10.1016/j.jad.2015.11.031

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  What do clinicians treat: Diagnoses or symptoms? The incremental validity of a symptom-based, dimensional characterization of emotional disorders in predicting medication prescription patterns.

Authors:  Monika A Waszczuk; Mark Zimmerman; Camilo Ruggero; Kaiqiao Li; Annmarie MacNamara; Anna Weinberg; Greg Hajcak; David Watson; Roman Kotov
Journal:  Compr Psychiatry       Date:  2017-04-18       Impact factor: 3.735

Review 2.  An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol.

Authors:  Amir Garakani; Rafael C Freire; Frank D Buono; Robyn P Thom; Kaitlyn Larkin; Melissa C Funaro; Mona Salehi; Mercedes M Perez-Rodriguez
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 3.  The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.

Authors:  Baptiste Pignon; Chloé Tezenas du Montcel; Louise Carton; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

4.  Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries.

Authors:  Matthias A Reinhard; Johanna Seifert; Timo Greiner; Sermin Toto; Stefan Bleich; Renate Grohmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-12-28       Impact factor: 5.270

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.